key: cord-0880141-9nri1ln6
authors: Kohmer, Niko; Westhaus, Sandra; Rühl, Cornelia; Ciesek, Sandra; Rabenau, Holger F.
title: Clinical performance of different SARS‐CoV‐2 IgG antibody tests
date: 2020-06-08
journal: J Med Virol
DOI: 10.1002/jmv.26145
sha: b681e72b2af409e35dd89c384eef884c11515708
doc_id: 880141
cord_uid: 9nri1ln6

SARS‐CoV‐2 serological assays are urgently needed for rapid diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS‐CoV‐2 IgG and Vircell COVID‐19 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID‐19 IgG/IgM Rapid Test Device) and two in‐house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)). We tested follow up serum/plasma samples of individuals PCR‐diagnosed with COVID‐19. Most of the SARS‐CoV‐2 samples were from individuals with moderate to severe clinical course, who required an in‐patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5‐9) and from 93.8 to 100% for the later period (days 10‐18). With exception of one sample, all positive tested COVID‐19 follow up‐samples, using the commercially available assays examined (including the in‐house developed IFA), demonstrated neutralizing properties in the PRNT. Regarding specificity, some samples of endemic coronavirus (HCoV‐OC43, HCoV‐229E) and Epstein Barr virus (EBV) infected individuals cross‐reacted in the ELISA assays and IFA, in one case generating a false positive result. This article is protected by copyright. All rights reserved.

SARS-CoV-2 is a new Coronavirus, belonging to the group of betacoronaviruses, which emerged in December 2019 in Wuhan, China. It is the causative agent of an acute respiratory disease known as coronavirus disease 2019 . The spectrum of clinical signs can be very broad and asymptomatic infections are reported. The virus has rapidly spread globally. On 11 March 2020 the World Health Organization (WHO) declared COVID-19 as a pandemic. Nucleic acid amplification testing (NAT) is the method of choice in the early phase of infection [Rabi et al., 2020] . However, to acquire knowledge about the seroprevalence of SARS-CoV-2 and to test for (potential) individual immunity, there is an increasing demand in the detection of antibodiesespecially of IgG antibodies. Convalescent plasma may be used for therapeutic or prophylactic approaches as vaccines and other drugs are under development [Rajendran et al., 2020] . For all these purposes, sensitive and especially highly specific antibody This article is protected by copyright. All rights reserved.

assays are needed. The spike (S) protein of SARS-CoV-2 has shown to be highly immunogenic and is the main target for neutralizing antibodies [Ou et al., 2020] .

Currently there are many S protein based commercially or in-house developed assays available, but there is limited data on how these tests perform with clinical samples and if the detected IgG antibodies provide protective immunity. This study aims to provide a quick overview on some of these assays (two commercially available ELISA assays, one LFA and two in-house developed assays (IFA and PRNT)), focusing on the detection and neutralization capacity of IgG antibodies in follow up serum or plasma samples of individuals with PCR-diagnosed infections with SARS-CoV-2. To assess potential cross-reactivity, we examined defined follow-up samples of individuals infected with endemic coronaviruses and other infectious diseases.

We collected follow up serum or plasma samples (in the following simply stated as samples) from individuals with PCR-diagnosed infections with SARS-CoV-2 (n=33) at different time points (TABLE 1) This article is protected by copyright. All rights reserved.

The FaStep (COVID-19 IgG/IgM) rapid test cassettes (COV-W32M, Assure Tech (Hangzhou) Co., Ltd, China) were used according to the manufacturer's recommendation. We have no details on the used antigen component. 10 µl serum and two drops of sample buffer were applied to the sample well. Test results were visually evaluated after 10 minutes.

The CE certified versions of the Euroimmun SARS-CoV-2 IgG ELISA (Euroimmun, Lübeck, Germany) and Vircell COVID-19 ELISA IgG (Vircell Spain S.L.U., Granada, Spain) were used, in an identical manner, according to the manufacturer's recommendation. Both ELISA assays use SARS-CoV-2 recombinant antigen from spike glycoprotein (S protein) and the Vircell ELISA additionally Nucleocapsid (N protein). Samples were diluted 1:101 or 1:20, respectively, in sample buffer and incubated at 37° for 60 min in a 96-well microtiter plate followed by each protocols washing and incubation cycles, including controls and required reagents. Optical density (OD) was measured for both assays at 450 nm using a Virclia microplate reader (Vircell Spain S.L.U., Granada, Spain). The titers were calculated and results interpreted according to each manufacturer's protocol.

For an immunofluorescence assay Vero cells (african green monkey, ATCC CCL-81 (American Type Culture Collection, Manassas, Virginia, USA)) were infected with SARS-CoV-2 and harvested two days post infection. Briefly, cells were trypsinized and washed once with PBS before transferred onto a 10-well diagnostic microscope slide.

After drying, cells were fixated with 100% ethanol for 10 minutes. Patient samples were This article is protected by copyright. All rights reserved. 

To test for the neutralizing capacity of SARS-CoV-2 specific antibodies, Caco-2 cells This article is protected by copyright. All rights reserved.

In the early phase of infection, from days 5-9 after PCR-confirmed infection with SARS-CoV-2, the in-house developed IFA and PRNT showed a sensitivity of 76.5% (13/17), the Vircell ELISA a sensitivity of 70.6% (12/17), the Assure Tech Rapid Test a sensitivity of 62.5% (10/16) and the Euroimmun ELISA a sensitivity of 58.8% 1 -Sensitivity and specificity of the examined SARS-CoV-2 IgG assays from days 5-9 and days 10-18. 

In terms of sensitivity, our data are consistent with previously published data. In a study from Liu et al., using an rS-based ELISA assay, the group found SARS-CoV-2 IgG antibodies in less than 60% of the samples from days 6-10 after disease onset. The sensitivity increased to >90% in samples from days 16-20 and from protective IgG antibodies against the S protein [Zhou and Zhao, 2020] ] using ELISA or lateral flow assays is more convenient and practicable than using the hands on-and time-intensive IFA or PRNT, which can only be performed by experienced personnel, and the PRNT, only in a BSL-3 laboratory. ELISA based assays can be automated and used for larger sample sizes. Lateral flow assays can be used by less experienced personnel in a point-of-care setting, generating results in short time. Some samples, however, were only detected with the IFA and PRNT as gold standard. The titer needed for potential protective immunity is not yet (officially) defined. In one study, it is reported, that an individual cleared SARS-CoV-2 without developing antibodies up to 46 days after illness . The mechanism of immunity, especially of protective immunity (if applicable) and how long it will last, need to be further investigated. Besides a humoral mediated immune response, there is evidence that Tcell mediated immunity plays a role [Tay et al., 2020] . Most of the SARS-CoV-2 samples analysed in this study were from individuals with moderate to severe clinical This article is protected by copyright. All rights reserved.

course, who required an in-patient hospital stay. In a Chinese study, male and female patients showed a higher IgG titer (female higher than male) in severe clinical status than in mild clinical status [Zeng et al., 2020] . We have also tested follow-up samples of individuals PCR-diagnosed with COVID-19 with mild or no symptoms at all, IgG antibodies could only be detected after 6 weeks (data not shown). In terms of specificity, cross-reacting antibodies of endemic coronavirus infected individuals or of individuals with other active infectious diseases (e.g. EBV or CMV) are a known phenomenon [Okba et al., 2020] . The examined assays in our study demonstrated a good specificity.

Only the Vircell ELISA generated one positive result for one HCoV-229E sample, whereas the Euroimmun ELISA generated only one borderline result for the HCoV- 

4-11) after the first COVID-19 positive result) of 30 hospitalized patients in Italy, a lateral flow assay detected IgM and IgG antibodies in 63.3% of the cases

using an in-house developed IFA, the group found seroconversion in all examined follow-up serum samples of COVID-19 patients by day 14 after onset of symptoms. The samples were further analyzed via PRNT, all showed neutralization activity against SARS-CoV-2

An important finding of our study is, that (with exception of sample 1) all detected SARS-CoV-2 IgG antibodies in the analyzed cohort, using the commercially available assays examined, demonstrated neutralizing (potentially protective) properties in the PRNT. The screening for SARS-CoV-2 IgG antibodies

Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department

Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

The trinity of COVID-19: immunity, inflammation and intervention

Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients

Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2)

A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2